Sonia Franciosi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sonia Franciosi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- James Schmeidler
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY
3 shared publications - Joseph Daniel Buxbaum
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 shared publications - Sam Gandy
Department of Neurology Icahn School of Medicine at Mount Sinai New York New York USA
3 shared publications - Daniel Fine English
School of Neuroscience, Virginia Tech, Blacksburg, VA, USA
2 shared publications - Dara L. Dickstein
Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications - Gregory A. Elder
Department of Neurology, Icahn School of Medicine at Mount Sinai
2 shared publications
Latest Publications
- Open Access
Feeding schedule and proteolysis regulate autophagic clearance of mutant huntingtin
The expression of mutant huntingtin (mHTT) causes Huntington disease (HD), and lowering its levels is therefore an attractive therapeutic strategy. Here we show that scheduled feeding significantly decreases mHTT protein levels through enhanced autophagy in the CNS of an HD mouse model, while short term fasting is sufficient to observe similar effects in peripheral tissue. Furthermore, preventing proteolysis at the caspase-6 cleavage site D586 (C6R) makes mHTT a better substrate for autophagy, additionally increasing its clearance. Mice expressing mutant C6R also exhibit increased autophagy at baseline compared to an HD model with cleavable mHTT, suggesting that the native function of HTT in promoting autophagy is disrupted upon cleavage and re-established by prevention of cleavage by caspase-6. In HD patients, mHTT clearance and autophagy may therefore become increasingly impaired as a function of age and disease stage by gradually increased activity of mHTT-processing enzymes.
Open AccessFeeding schedule and proteolysis regulate autophagic clearance of mutant huntingtin
The expression of mutant huntingtin (mHTT) causes Huntington disease (HD), and lowering its levels is therefore an attractive therapeutic strategy. Here we show that scheduled feeding significantly decreases mHTT protein levels through enhanced autophagy in the CNS of an HD mouse model, while short term fasting is sufficient to observe similar effects in peripheral tissue. Furthermore, preventing proteolysis at the caspase-6 cleavage site D586 (C6R) makes mHTT a better substrate for autophagy, additionally increasing its clearance. Mice expressing mutant C6R also exhibit increased autophagy at baseline compared to an HD model with cleavable mHTT, suggesting that the native function of HTT in promoting autophagy is disrupted upon cleavage and re-established by prevention of cleavage by caspase-6. In HD patients, mHTT clearance and autophagy may therefore become increasingly impaired as a function of age and disease stage by gradually increased activity of mHTT-processing enzymes.
- 8 January 2012
- Published by Wiley in Clinical Genetics
- Vol. 81 (5) , 431
A novel approach to the management and use of personal genome variants in clinical practice
- 8 January 2012
- Published by Wiley in Clinical Genetics
- Vol. 81 (5) , 431
A novel approach to the management and use of personal genome variants in clinical practice
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 538-540
De novo nonsense mutations in the sodium channel gene, SCN2A, in sporadic intractable epilepsy
De novo mutations of voltage‐gated sodium channel αII gene SCN2A in intractable epilepsies Ogiwara et al. (2009)Neurology 73(13): 1046–1053
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 538-540
De novo nonsense mutations in the sodium channel gene, SCN2A, in sporadic intractable epilepsy
De novo mutations of voltage‐gated sodium channel αII gene SCN2A in intractable epilepsies Ogiwara et al. (2009)Neurology 73(13): 1046–1053
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 536-538
HDAC7: a viable target in the treatment of cystic fibrosis
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 536-538
HDAC7: a viable target in the treatment of cystic fibrosis
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 535-536
Nexilin: a potential novel factor contributing to dilated cardiomyopathy
Nexilin mutations destabilize z‐disks and lead to dilated cardiomyopathy Hassel et al. (2009)Nature Medicine 15(11): 1281–1288
- 9 May 2010
- Published by Wiley in Clinical Genetics
- Vol. 77 (6) , 535-536
Nexilin: a potential novel factor contributing to dilated cardiomyopathy
Nexilin mutations destabilize z‐disks and lead to dilated cardiomyopathy Hassel et al. (2009)Nature Medicine 15(11): 1281–1288
- Open Access
- 14 January 2010
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 5 (1) , 1
Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease
Background: The low-density lipoprotein receptor related protein 1 (LRP1) has been implicated in Alzheimer's disease (AD) but its signalling has not been fully evaluated. There is good evidence that the cytoplasmic domain of LRP1 is involved in protein-protein interactions, important in the cell biology of LRP1. Results: We carried out three yeast two-hybrid screens to identify proteins that interact with the cytoplasmic domain of LRP1. The screens included both conventional screens as well as a novel, split-ubiquitin-based screen in which an LRP1 construct was expressed and screened as a transmembrane protein. The split-ubiquitin screen was validated in a screen using full-length amyloid protein precursor (APP), which successfully identified FE65 and FE65L2, as well as novel interactors (Rab3a, Napg, and ubiquitin b). Using both a conventional screen as well as the split-ubiquitin screen, we identified NYGGF4 as a novel LRP1 interactor. The interaction between LRP1 and NYGGF4 was validated using two-hybrid assays, coprecipitation and colocalization in mammalian cells. Mutation analysis demonstrated a specific interaction of NYGGF4 with an NPXY motif that required an intact tyrosine residue. Interestingly, while we confirmed that other LRP1 interactors we identified, including JIP1B and EB-1, were also able to bind to APP, NYGGF4 was unique in that it showed specific binding with LRP1. Expression of NYGGF4 decreased significantly in patients with AD as compared to age-matched controls, and showed decreasing expression with AD disease progression. Examination of Nyggf4 expression in mice with different alleles of the human APOE4 gene showed significant differences in Nyggf4 expression. Conclusions: These results implicate NYGGF4 as a novel and specific interactor of LRP1. Decreased expression of LRP1 and NYGGF4 over disease, evident with the presence of even moderate numbers of neuritic plaques, suggests that LRP1-NYGGF4 is a system altered early in disease. Genetic and functional studies have implicated both LRP1 and NYGGF4 in obesity and cardiovascular disease and the physical association of these proteins may reflect a common mechanism. This is particularly interesting in light of the dual role of ApoE in both cardiovascular risk and AD. The results support further studies on the functional relationship between NYGGF4 and LRP1.
- 14 January 2010
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 5 (1) , 1
Open AccessExtensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease
Background: The low-density lipoprotein receptor related protein 1 (LRP1) has been implicated in Alzheimer's disease (AD) but its signalling has not been fully evaluated. There is good evidence that the cytoplasmic domain of LRP1 is involved in protein-protein interactions, important in the cell biology of LRP1. Results: We carried out three yeast two-hybrid screens to identify proteins that interact with the cytoplasmic domain of LRP1. The screens included both conventional screens as well as a novel, split-ubiquitin-based screen in which an LRP1 construct was expressed and screened as a transmembrane protein. The split-ubiquitin screen was validated in a screen using full-length amyloid protein precursor (APP), which successfully identified FE65 and FE65L2, as well as novel interactors (Rab3a, Napg, and ubiquitin b). Using both a conventional screen as well as the split-ubiquitin screen, we identified NYGGF4 as a novel LRP1 interactor. The interaction between LRP1 and NYGGF4 was validated using two-hybrid assays, coprecipitation and colocalization in mammalian cells. Mutation analysis demonstrated a specific interaction of NYGGF4 with an NPXY motif that required an intact tyrosine residue. Interestingly, while we confirmed that other LRP1 interactors we identified, including JIP1B and EB-1, were also able to bind to APP, NYGGF4 was unique in that it showed specific binding with LRP1. Expression of NYGGF4 decreased significantly in patients with AD as compared to age-matched controls, and showed decreasing expression with AD disease progression. Examination of Nyggf4 expression in mice with different alleles of the human APOE4 gene showed significant differences in Nyggf4 expression. Conclusions: These results implicate NYGGF4 as a novel and specific interactor of LRP1. Decreased expression of LRP1 and NYGGF4 over disease, evident with the presence of even moderate numbers of neuritic plaques, suggests that LRP1-NYGGF4 is a system altered early in disease. Genetic and functional studies have implicated both LRP1 and NYGGF4 in obesity and cardiovascular disease and the physical association of these proteins may reflect a common mechanism. This is particularly interesting in light of the dual role of ApoE in both cardiovascular risk and AD. The results support further studies on the functional relationship between NYGGF4 and LRP1.
- Open Access
- 24 October 2009
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 4 (1) , 42
Novel cerebrovascular pathology in mice fed a high cholesterol diet
Background: Hypercholesterolemia causes atherosclerosis in medium to large sized arteries. Cholesterol is less known for affecting the microvasculature and has not been previously reported to induce microvascular pathology in the central nervous system (CNS). Results: Mice with a null mutation in the low-density lipoprotein receptor (LDLR) gene as well as C57BL/6J mice fed a high cholesterol diet developed a distinct microvascular pathology in the CNS that differs from cholesterol-induced atherosclerotic disease. Microvessel diameter was increased but microvascular density and length were not consistently affected. Degenerative changes and thickened vascular basement membranes were present ultrastructurally. The observed pathology shares features with the microvascular pathology of Alzheimer's disease (AD), including the presence of string-like vessels. Brain apolipoprotein E levels which have been previously found to be elevated in LDLR-/- mice were also increased in C57BL/6J mice fed a high cholesterol diet. Conclusion: In addition to its effects as an inducer of atherosclerosis in medium to large sized arteries, hypercholesterolemia also induces a microvascular pathology in the CNS that shares features of the vascular pathology found in AD. These observations suggest that high cholesterol may induce microvascular disease in a range of CNS disorders including AD.
- 24 October 2009
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 4 (1) , 42
Open AccessNovel cerebrovascular pathology in mice fed a high cholesterol diet
Background: Hypercholesterolemia causes atherosclerosis in medium to large sized arteries. Cholesterol is less known for affecting the microvasculature and has not been previously reported to induce microvascular pathology in the central nervous system (CNS). Results: Mice with a null mutation in the low-density lipoprotein receptor (LDLR) gene as well as C57BL/6J mice fed a high cholesterol diet developed a distinct microvascular pathology in the CNS that differs from cholesterol-induced atherosclerotic disease. Microvessel diameter was increased but microvascular density and length were not consistently affected. Degenerative changes and thickened vascular basement membranes were present ultrastructurally. The observed pathology shares features with the microvascular pathology of Alzheimer's disease (AD), including the presence of string-like vessels. Brain apolipoprotein E levels which have been previously found to be elevated in LDLR-/- mice were also increased in C57BL/6J mice fed a high cholesterol diet. Conclusion: In addition to its effects as an inducer of atherosclerosis in medium to large sized arteries, hypercholesterolemia also induces a microvascular pathology in the CNS that shares features of the vascular pathology found in AD. These observations suggest that high cholesterol may induce microvascular disease in a range of CNS disorders including AD.